Hanwha Pharm ordeded to distribute Livial

The Seoul District Court accepted on November 25 the request of Hanwha Pharm to seek an injunction trial against the Korea Food and Drug Administration to invalidate cancellation of the product license of Livial, a first choice comprehensive treatment for the relief of climacteric symptoms in postmenopausal women.

Thus, Livial can be distributed in domestic market until the court's examinati...